Abstract
Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.
Original language | English (US) |
---|---|
Pages (from-to) | 268-272 |
Number of pages | 5 |
Journal | European Urology Oncology |
Volume | 5 |
Issue number | 3 |
DOIs | |
State | Published - Jun 1 2022 |
ASJC Scopus subject areas
- General Medicine